Sinclair Pharma can help those with itchy skin or bleeding gums. The specialty pharmaceutical development company acquires oral health and dermatology companies that have already begun developing products and turns them into new lines or line extensions for commercial sale. Its top sellers include Aloclair for mouth ulcers, Decapinol for gingivitis, and Atopiclair for ezcema. It has a sales presence in the UK, France, Italy, Portugal, and Spain, with marketing partners in more than 80 countries. When former CEO Michael Flynn led a management buy-in in 2000, Sinclair's strategy shifted from being a traditional early research and development company to an acquisition vehicle of late-stage development products.

LGC (Holdings) Limited company provides chemical, DNA and other scientific analysis through four operating divisions: LGC forensics, life and food sciences, research and technology, and LGC standards. Its customers are involved in such areas as drug development, health care services, chemicals and petrochemicals, law enforcement, and environmental quality and maintenance. The company's LGC Prochem unit sells enzymes, proteins, reagents, and other laboratory supplies. Investment firm 3i Group owns about 30% of LGC, as does its employees.

Sinovac Biotech Ltd. is a profitable biopharmaceutical company headquartered in Beijing, China. The Company focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. Sinovac received approval in 2009 for its H1N1 influenza vaccine, PANFLU.1 and has commenced fulfilling orders from the Chinese Central Government pursuit to the government stockpiling program. Sinovac was the first company worldwide to receive approval for H1N1 influenza vaccine.

Prestige Brands Holdings was founded in 1996 and is headquartered in Irvington, New York. Prestige Brands Holdings, Inc. (Prestige) sells over-the-counter healthcare, household cleaning and personal care products in a global marketplace. The Company’s products are sold through multiple channels, including mass merchandisers and drug, grocery, dollar and club stores, which allow it to launch products across all distribution channels and reduce its exposure to any single distribution channel. The Company conducts its operations through three principal business segments: over-the-counter healthcare, household cleaning and personal care. During the fiscal year ended March 31, 2009 (fiscal 2009), Prestige’s principal brands accounted for approximately 94.5% of its net revenues.

Morphotek has mighty morphin' power, but don't expect to find its products on the shelves of the local toy store. The biotechnology company develops monoclonal antibody (single-source protein) therapies for the treatment of cancer, inflammation, and infectious diseases using its proprietary Morphogenics technology platform. It conducts research and clinical development programs on its own drug candidates for ailments such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. Morphotek also enters collaborative research partnerships and licenses out its technology to other drug companies such as Amgen and Novo Nordisk. The company is a subsidiary of Eisai Inc., part of Japanese drug firm Eisai.

Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland. Trinity Biotech plc develops, acquires, manufactures, distributes, and sells diagnostic test kits and instrumentation worldwide. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, sexually transmitted diseases, blood coagulation, and autoimmune disorders. It also sells raw materials to the life sciences industry. In addition, the company offers point of care diagnostic tests, which are carried out in the presence of the patient, principally to diagnose the presence of HIV antibodies in the patient. Its customers include hospitals, clinical laboratories, commercial reference laboratories, and research institutions. The company sells its products through distributor partners, as well as directly in the United States, the United Kingdom, France, and Germany.

Nature's Way Holding Company manufactures and markets nutritional supplements and other OTC products which are sold with the Enzymatic Therapy, Nature's Way, and Remifemin labels through natural foods retailers and mass market retailers in the US. Its products are aimed to alleviate everything from sleeplessness to hot flashes and are distributed throughout the US and to more than 40 other countries. Its Integrative Therapeutics and Vitaline brands are sold through healthcare practitioners' offices. The company is a unit of German firm Dr. Willmar Schwabe Pharmaceuticals.

Ondine Biopharma wants to offer an alternative to antibiotics for treating infections. The company is focused on the development and commercialization of its patented light-activated technology, called photodynamic disinfection, as a therapy for bacterial, fungal, and viral infections. Ondine Biopharma is developing a nasal system called MRSAid that incorporates hardware and photosensitizers to help treat often deadly hospital-acquired pathogens, such as staph infections. If commercialized, that product would give the company entry into the hospital infection control market.

IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

Antisoma plc company was founded in 1988. Antisoma is anti-cancer. The drug development firm scouts academic or cancer research institutions for promising new oncology drug candidates and snaps them up. Once the drugs are in its pipeline, Antisoma conducts preclinical and clinical trials. The company's leading candidates in clinical trials include possible treatments for lung cancer, acute myeloid leukemia, and breast cancer. Its 2008 acquisition of Xanthus Pharmaceuticals brought along more candidates, and helped Antisoma expand in the US. Antisoma also partners with larger drug makers and research groups, including Novartis, to develop and commercialize products.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.